1
|
Ponomarev AV, Shubina IZ. Insights Into Mechanisms of Tumor and Immune System Interaction: Association With Wound Healing. Front Oncol 2019; 9:1115. [PMID: 31709183 PMCID: PMC6823879 DOI: 10.3389/fonc.2019.01115] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Accepted: 10/07/2019] [Indexed: 12/14/2022] Open
Abstract
A large number of studies have presented a great deal of information about tumor and immune system interaction. Nevertheless, the problem of tumor evasion from the immune reaction is still difficult to resolve. Understanding the ways in which immunosuppressive tumor microenvironment develops and maintains its potential is of utmost importance to ensure the best use of the suppressed immune functions. The study presents a review covering the data on tumor-associated antigens, mechanisms of tumor evasion from the immune reactions, and search for common immunosuppressive processes of tumor growth and normal wound healing. The study discusses the important role of monocytes/macrophages in the regulation of immune system reactions. We suggest that the simultaneous actions of growth factors and pro-inflammatory cytokines may result in the suppression of the immune system. The study describes intracellular signaling molecules that take part in the regulation of the myeloid cell functions. If the hypothesis is proved correct, the indicated interaction of cytokines could be regarded as a prospective target for antitumor therapy.
Collapse
Affiliation(s)
| | - Irina Zh Shubina
- N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
| |
Collapse
|
2
|
Wang L, Kumar M, Deng Q, Wang X, Liu M, Gong Z, Zhang S, Ma X, Xu-Monette ZY, Xiao M, Yi Q, Young KH, Ramos KS, Li Y. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice. Cancer Lett 2018; 440-441:135-144. [PMID: 30343114 DOI: 10.1016/j.canlet.2018.10.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Revised: 09/11/2018] [Accepted: 10/09/2018] [Indexed: 01/18/2023]
Abstract
Although epidemiologic studies have suggested a possible association between occupational exposures to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and the risk of development of multiple myeloma, definitive evidence in support of this association is lacking. In the present study, we employed the Vk*Myc mouse model of multiple myeloma to assess the impact of TCDD exposure on multiple myeloma pathogenesis. TCDD induced splenomegaly and multiple peripheral blood abnormalities, including anemia and high serum IgG levels. In addition, TCDD triggered bone lytic lesions, as well as renal tubular casts, a phenomenon associated with human myeloma kidney disease. Even in wild-type C57BL/6 mice, TCDD increased serum IgG levels, induced anemia, and increased plasma cell presence in the spleen and bone marrow, hallmarks of benign monoclonal gammopathy. Lastly, TCDD induced AKT activation and the DNA damage response, key pathogenic events in myeloma pathogenesis, in animal spleen and/or bone marrow. These data indicate that TCDD accelerates monoclonal gammopathy development and promotes progression to multiple myeloma in genetically-predisposed mice. This work offers the first direct experimental evidence establishing TCDD as an environmental risk factor for monoclonal gammopathy of undetermined significance and multiple myeloma.
Collapse
Affiliation(s)
- Lei Wang
- Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou, China; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Munish Kumar
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Raman Fellow (UGC), Department of Biochemistry, University of Allahabad, Allahabad, India
| | - Qipan Deng
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Xu Wang
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Ming Liu
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
| | - Zhaojian Gong
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Stomatology, The Second Xiangya Hospital, Central South University, Changsha, China
| | - Shanshan Zhang
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Stomatology, Xiangya Hospital, Central South University, Changsha, China
| | - Xiaodong Ma
- Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou, China; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Zijun Y Xu-Monette
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Min Xiao
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Qing Yi
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Ken H Young
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Kenneth S Ramos
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA
| | - Yong Li
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
| |
Collapse
|
3
|
Bieghs L, Johnsen HE, Maes K, Menu E, Van Valckenborgh E, Overgaard MT, Nyegaard M, Conover CA, Vanderkerken K, De Bruyne E. The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential. Oncotarget 2018; 7:48732-48752. [PMID: 27129151 PMCID: PMC5217049 DOI: 10.18632/oncotarget.8982] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2016] [Accepted: 04/16/2016] [Indexed: 12/14/2022] Open
Abstract
Multiple myeloma (MM) is a highly heterogeneous plasma cell malignancy. The MM cells reside in the bone marrow (BM), where reciprocal interactions with the BM niche foster MM cell survival, proliferation, and drug resistance. As in most cancers, the insulin-like growth factor (IGF) system has been demonstrated to play a key role in the pathogenesis of MM. The IGF system consists of IGF ligands, IGF receptors, IGF binding proteins (IGFBPs), and IGFBP proteases and contributes not only to the survival, proliferation, and homing of MM cells, but also MM-associated angiogenesis and osteolysis. Furthermore, increased IGF-I receptor (IGF-IR) expression on MM cells correlates with a poor prognosis in MM patients. Despite the prominent role of the IGF system in MM, strategies targeting the IGF-IR using blocking antibodies or small molecule inhibitors have failed to translate into the clinic. However, increasing preclinical evidence indicates that IGF-I is also involved in the development of drug resistance against current standard-of-care agents against MM, including proteasome inhibitors, immunomodulatory agents, and corticoids. IGF-IR targeting has been able to overcome or revert this drug resistance in animal models, enhancing the efficacy of standard-of-care agents. This finding has generated renewed interest in the therapeutic potential of IGF-I targeting in MM. The present review provides an update of the impact of the different IGF system components in MM and discusses the diagnostic and therapeutic potentials.
Collapse
Affiliation(s)
- Liesbeth Bieghs
- Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium.,Department of Hematology, Aalborg Hospital, Aalborg University, Denmark.,Department of Biomedicin, Aarhus University, Aarhus, Denmark
| | - Hans E Johnsen
- Department of Hematology, Aalborg Hospital, Aalborg University, Denmark.,Clinical Cancer Research Center, Aalborg University Hospital, Denmark.,Department of Clinical Medicine, Aalborg University, Denmark
| | - Ken Maes
- Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| | - Eline Menu
- Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| | - Els Van Valckenborgh
- Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| | | | - Mette Nyegaard
- Department of Biomedicin, Aarhus University, Aarhus, Denmark
| | - Cheryl A Conover
- Division of Endocrinology, Metabolism and Nutrition, Endocrine Research Unit, Mayo Clinic, Rochester, NY, USA
| | - Karin Vanderkerken
- Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| | - Elke De Bruyne
- Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium
| |
Collapse
|
4
|
Perez‐Cornago A, Appleby PN, Tipper S, Key TJ, Allen NE, Nieters A, Vermeulen R, Roulland S, Casabonne D, Kaaks R, Fortner RT, Boeing H, Trichopoulou A, La Vecchia C, Klinaki E, Hansen L, Tjønneland A, Bonnet F, Fagherazzi G, Boutron‐Ruault M, Pala V, Masala G, Sacerdote C, Peeters PH, Bueno‐de‐Mesquita HB, Weiderpass E, Dorronsoro M, Quirós JR, Barricarte A, Gavrila D, Agudo A, Borgquist S, Rosendahl AH, Melin B, Wareham N, Khaw K, Gunter M, Riboli E, Vineis P, Travis RC. Prediagnostic circulating concentrations of plasma insulin-like growth factor-I and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2017; 140:1111-1118. [PMID: 27870006 PMCID: PMC5299544 DOI: 10.1002/ijc.30528] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Revised: 10/19/2016] [Accepted: 10/28/2016] [Indexed: 12/20/2022]
Abstract
Insulin-like growth factor (IGF)-I has cancer promoting activities. However, the hypothesis that circulating IGF-I concentration is related to risk of lymphoma overall or its subtypes has not been examined prospectively. IGF-I concentration was measured in pre-diagnostic plasma samples from a nested case-control study of 1,072 cases of lymphoid malignancies and 1,072 individually matched controls from the European Prospective Investigation into Cancer and Nutrition. Odds ratios (ORs) and confidence intervals (CIs) for lymphoma were calculated using conditional logistic regression. IGF-I concentration was not associated with overall lymphoma risk (multivariable-adjusted OR for highest versus lowest third = 0.77 [95% CI = 0.57-1.03], ptrend = 0.06). There was no statistical evidence of heterogeneity in this association with IGF-I by sex, age at blood collection, time between blood collection and diagnosis, age at diagnosis, or body mass index (pheterogeneity for all ≥ 0.05). There were no associations between IGF-I concentration and risk for specific BCL subtypes, T-cell lymphoma or Hodgkin lymphoma, although number of cases were small. In this European population, IGF-I concentration was not associated with risk of overall lymphoma. This study provides the first prospective evidence on circulating IGF-I concentrations and risk of lymphoma. Further prospective data are required to examine associations of IGF-I concentrations with lymphoma subtypes.
Collapse
Affiliation(s)
- Aurora Perez‐Cornago
- Nuffield Department of Population Health, Cancer Epidemiology UnitUniversity of OxfordOxfordUnited Kingdom
| | - Paul N. Appleby
- Nuffield Department of Population Health, Cancer Epidemiology UnitUniversity of OxfordOxfordUnited Kingdom
| | - Sarah Tipper
- Nuffield Department of Population Health, Cancer Epidemiology UnitUniversity of OxfordOxfordUnited Kingdom
| | - Timothy J. Key
- Nuffield Department of Population Health, Cancer Epidemiology UnitUniversity of OxfordOxfordUnited Kingdom
| | - Naomi E. Allen
- Clinical Trial Service Unit and Epidemiological Studies Unit, University of OxfordOxfordUnited Kingdom
| | - Alexandra Nieters
- Center for Chronic Immunodeficiency, Molecular EpidemiologyUniversity Medical Center FreiburgFreiburgGermany
| | - Roel Vermeulen
- Institute for Risk Assessment Sciences, Division Environmental Epidemiology, Utrecht UniversityUtrechtThe Netherlands
| | - Sandrine Roulland
- Centre d'Immunologie de Marseille‐Luminy, Université d'Aix‐Marseille UM2, Inserm, U1104, CNRSMarseilleFrance
| | - Delphine Casabonne
- Unit of Infections and Cancer (UNIC), IDIBELL, Institut Català d'Oncologia, 08907 L'Hospitalet de LlobregatBarcelonaSpain
- CIBER Epidemiología y Salud Pública (CIBERESP)MadridSpain
| | - Rudolf Kaaks
- Division of Cancer EpidemiologyGerman Cancer Research Center (DKFZ)HeidelbergGermany
| | - Renee T. Fortner
- Division of Cancer EpidemiologyGerman Cancer Research Center (DKFZ)HeidelbergGermany
| | - Heiner Boeing
- Department of EpidemiologyGerman Institute of Human Nutrition Potsdam‐RehbrückeNuthetalGermany
| | - Antonia Trichopoulou
- Hellenic Health FoundationAthensGreece
- Department of Hygiene, Epidemiology and Medical Statistics, WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public HealthUniversity of Athens Medical SchoolGreece
| | - Carlo La Vecchia
- Hellenic Health FoundationAthensGreece
- Department of Clinical Sciences and Community Health Università degli Studi di MilanoItaly
| | | | - Louise Hansen
- Danish Cancer Society Research CenterCopenhagenDenmark
| | | | - Fabrice Bonnet
- Université Paris‐Saclay, Université Paris‐Sud, UVSQ, CESP, INSERMVillejuifFrance
- Gustave RoussyVillejuifFrance
- CHU Rennes, University Rennes 1RennesFrance
| | - Guy Fagherazzi
- Université Paris‐Saclay, Université Paris‐Sud, UVSQ, CESP, INSERMVillejuifFrance
- Gustave RoussyVillejuifFrance
| | | | - Valeria Pala
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei TumoriMilanoItaly
| | - Giovanna Masala
- Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute—ISPOFlorenceItaly
| | - Carlotta Sacerdote
- Unit of Cancer Epidemiology, AO Citta' della Salute e della Scienza‐University of Turin and Center for Cancer Prevention (CPO‐Piemonte)TurinItaly
| | - Petra H. Peeters
- Department of Epidemiology, Julius Center for Health Sciences and Primary CareUniversity Medical Center UtrechtThe Netherlands
- Department of Epidemiology and Biostatistics, MRC‐PHE Centre for Environment and Health, School of Public HealthImperial CollegeLondonUnited Kingdom
| | - H. B(as) Bueno‐de‐Mesquita
- Department for Determinants of Chronic Diseases (DCD)National Institute for Public Health and the Environment (RIVM)BilthovenThe Netherlands
- Department of Epidemiology and Biostatistics, School of Public HealthImperial College LondonLondonUnited Kingdom
- Department of Social & Preventive Medicine, Faculty of MedicineUniversity of MalayaKuala LumpurMalaysia
| | - Elisabete Weiderpass
- Department of Community Medicine, Faculty of Health SciencesUniversity of Tromsø, The Arctic University of NorwayTromsøNorway
- Department of Research, Cancer Registry of NorwayInstitute of Population‐Based Cancer ResearchOsloNorway
- Department of Medical Epidemiology and BiostatisticsKarolinska InstitutetStockholmSweden
- Genetic Epidemiology Group, Folkhälsan Research CenterHelsinkiFinland
| | - Miren Dorronsoro
- Basque Regional Health Department San SebastianPublic Health Direction and Biodonostia‐ CiberespSpain
| | | | - Aurelio Barricarte
- CIBER Epidemiología y Salud Pública (CIBERESP)MadridSpain
- Navarra Public Health InstitutePamplonaSpain
- Navarra Institute for Health Research (IdiSNA)PamplonaSpain
| | - Diana Gavrila
- CIBER Epidemiología y Salud Pública (CIBERESP)MadridSpain
- Department of EpidemiologyMurcia Regional Health Council, IMIB‐ArrixacaMurciaSpain
| | - Antonio Agudo
- Unit of Nutrition and Cancer, Cancer Epidemiology Research ProgramCatalan Institute of Oncology‐IDIBELL, L'Hospitalet de LlobregatBarcelonaSpain
| | - Signe Borgquist
- Department of Clinical Sciences Lund, Division of Oncology and PathologyLund University, Faculty of MedicineLundSweden
| | - Ann H. Rosendahl
- Department of Clinical Sciences Lund, Division of Oncology and PathologyLund University, Faculty of MedicineLundSweden
| | - Beatrice Melin
- Department of Radiation SciencesOncology Umeå UniversityUmeåSweden
| | - Nick Wareham
- MRC Epidemiology Unit, University of CambridgeCambridgeUnited Kingdom
| | - Kay‐Tee Khaw
- University of Cambridge School of Clinical MedicineCambridgeUnited Kingdom
| | - Marc Gunter
- Department of Epidemiology and Biostatistics, School of Public HealthImperial College LondonLondonUnited Kingdom
- Section of Nutrition and Metabolism, International Agency for Research on CancerLyonFrance
| | - Elio Riboli
- Department of Epidemiology and Biostatistics, School of Public HealthImperial College LondonLondonUnited Kingdom
| | - Paolo Vineis
- Department of Epidemiology and Biostatistics, School of Public HealthImperial College LondonLondonUnited Kingdom
| | - Ruth C. Travis
- Nuffield Department of Population Health, Cancer Epidemiology UnitUniversity of OxfordOxfordUnited Kingdom
| |
Collapse
|
5
|
RUI MINGZHONG, HUANG ZHANPING, LIU YING, WANG ZIYAN, LIU RUI, FU JINXIANG, HUANG HAIWEN. Rosiglitazone suppresses angiogenesis in multiple myeloma via downregulation of hypoxia-inducible factor-1α and insulin-like growth factor-1 mRNA expression. Mol Med Rep 2014; 10:2137-43. [DOI: 10.3892/mmr.2014.2407] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2013] [Accepted: 04/14/2014] [Indexed: 11/06/2022] Open
|
6
|
McCranor BJ, Kim MJ, Cruz NM, Xue QL, Berger AE, Walston JD, Civin CI, Roy CN. Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells. Blood Cells Mol Dis 2014; 52:126-33. [PMID: 24119518 PMCID: PMC3947197 DOI: 10.1016/j.bcmd.2013.09.004] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2013] [Revised: 09/05/2013] [Accepted: 09/05/2013] [Indexed: 12/21/2022]
Abstract
Anemia of inflammation or chronic disease is a highly prevalent form of anemia. The inflammatory cytokine interleukin-6 (IL-6) negatively correlates with hemoglobin concentration in many disease states. The IL-6-hepcidin antimicrobial peptide axis promotes iron-restricted anemia; however the full role of IL-6 in anemia of inflammation is not well-defined. We previously reported that chronic inflammation had a negative impact on maturation of erythroid progenitors in a mouse model. We hypothesized that IL-6 may be responsible for impaired erythropoiesis, independent of iron restriction. To test the hypothesis we utilized the human erythroleukemia TF-1 cell line to model erythroid maturation and exposed them to varying doses of IL-6 over six days. At 10 ng/ml, IL-6 significantly repressed erythropoietin-dependent TF-1 erythroid maturation. While IL-6 did not decrease the expression of genes associated with hemoglobin synthesis, we observed impaired hemoglobin synthesis as demonstrated by decreased benzidine staining. We also observed that IL-6 down regulated expression of the gene SLC4a1 which is expressed late in erythropoiesis. Those findings suggested that IL-6-dependent inhibition of hemoglobin synthesis might occur. We investigated the impact of IL-6 on mitochondria. IL-6 decreased the mitochondrial membrane potential at all treatment doses, and significantly decreased mitochondrial mass at the highest dose. Our studies indicate that IL-6 may impair mitochondrial function in maturing erythroid cells resulting in impaired hemoglobin production and erythroid maturation. Our findings may indicate a novel pathway of action for IL-6 in the anemia of inflammation, and draw attention to the potential for new therapeutic targets that affect late erythroid development.
Collapse
Affiliation(s)
- Bryan J McCranor
- Division of Geriatric Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
| | - Min Jung Kim
- Center for Stem Cell Biology & Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Nicole M Cruz
- Division of Geriatric Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
| | - Qian-Li Xue
- Division of Geriatric Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
| | - Alan E Berger
- Lowe Family Genomics Core, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
| | - Jeremy D Walston
- Division of Geriatric Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
| | - Curt I Civin
- Center for Stem Cell Biology & Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Cindy N Roy
- Division of Geriatric Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA; Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA.
| |
Collapse
|